Thermo Fisher Scientific (TMO) closed trading at $175.3 on July 27, 2017. It has a 50-day moving average of $176.8 and a 200-day moving average of $163.3. On July 27, 2017, Thermo Fisher Scientific’s stock was trading ~22.9% above its 52-week low of $139.1 on December 1, 2016, and ~8.4% below its 52-week high of $182.9 on July 24, 2017. The company’s stock price has been on a bullish trajectory recently.
Thermo Fisher Scientific’s stock price gained more than 1% on July 26, 2017, as the company announced strong earnings results for 2Q17. The company’s revenues and earnings exceeded analysts’ estimates. The company’s growth came from all the company’s business segments and was attributed to strong end markets. Its growth was driven largely by its focus on emerging market expansion, innovation, and strategic expansion through inorganic growth.
As of July 28, 2017, Thermo Fisher Scientific’s peers Becton Dickinson (BDX), Abbott Laboratories (ABT), and Stryker (SYK) had generated returns of 16%, 16.7%, and 27%, respectively, during the past 12 months.
Comparisons with industry and market performances
Thermo Fisher Scientific has risen ~11.7% in the past 12 months. The company’s stock underperformed the broader market, as represented by the S&P 500 Index, which returned ~14% during the same period.
Thermo Fisher Scientific’s stock performance can also be compared to the performance of the broader US healthcare sector, represented by the Health Care Select Sector SPDR ETF (XLV). XLV has returned more than 6% during the past 12 months. Thermo Fisher Scientific returned ~24% on a year-to-date basis. The figure compares to 10.6% and 15.4% returns generated by the market and XLV, respectively.